Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Emyria Ltd ( (AU:EMD) ) just unveiled an update.
Emyria Limited has entered into a landmark multi-year agreement with Medibank Private Ltd to fund its Treatment-Resistant Depression (TRD) program at Perth Clinic. This agreement marks the first time a major Australian health insurer will fund a psychotherapy-led TRD program, significantly reducing financial barriers for eligible patients. This initiative builds on Medibank’s existing support for Emyria’s PTSD treatment program and further validates Emyria’s psychiatrist-led care model. With two funded programs now operational, Emyria is well-positioned for scalable growth and to make a lasting impact on mental health care in Australia.
More about Emyria Ltd
Emyria Limited is a leader in developing and delivering innovative mental health treatments, focusing on providing insurer-backed care for patients with urgent, high-need mental health conditions such as treatment-resistant depression (TRD) and PTSD.
Average Trading Volume: 4,113,597
Technical Sentiment Signal: Buy
Current Market Cap: A$33.21M
Find detailed analytics on EMD stock on TipRanks’ Stock Analysis page.